Celldex Therapeutics (CLDX)
(Delayed Data from NSDQ)
$37.17 USD
+0.81 (2.23%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $37.13 -0.04 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CLDX 37.17 +0.81(2.23%)
Will CLDX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CLDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLDX
Wall Street Analysts Think Celldex (CLDX) Could Surge 87.27%: Read This Before Placing a Bet
Wall Street Analysts Believe Celldex (CLDX) Could Rally 67.77%: Here's is How to Trade
CLDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Down -14.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
All You Need to Know About Celldex (CLDX) Rating Upgrade to Buy
Down -17.39% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
Other News for CLDX
Jasper Therapeutics initiated with bullish view at Stifel, here's why
First Week of CLDX February 2025 Options Trading
Stifel starts Celldex at buy, sees lead drug as potential blockbuster
Buy Rating on Celldex’s Barzolvolimab: A Potential Best-in-Class Biologic for Chronic Spontaneous Urticaria
Celldex initiated with bullish view at Stifel, here's why